Literature DB >> 3403313

The meningioma controversy: postoperative radiation therapy.

B W Taylor1, R B Marcus, W A Friedman, W E Ballinger, R R Million.   

Abstract

Total surgical excision is the main goal of therapy for intracranial meningiomas. The controversy today involves the efficacy of postoperative radiation therapy. To evaluate this question, 132 patients with benign intracranial meningiomas, treated between October 1964 and April 1985, were evaluated. All patients had a minimum 2-year follow-up. The actuarial local control rates at 10 years for the three treatment groups were as follows: subtotal excision alone, 18%; subtotal excision plus postoperative radiation therapy, 82%; and total excision alone, 77%. The actuarial determinate survival rates at 10 years were 49%, 81%, and 93%, respectively. Postoperative radiation therapy was also effective for patients treated at the time of the first recurrence, with an actuarial local control rate at 10 years after salvage treatment of 30% for patients treated with surgery alone and 89% for patients receiving postoperative radiation therapy at the time of salvage. This analysis suggests that radiation therapy has a significant role in the treatment of subtotally excised and recurrent intracranial meningiomas.

Entities:  

Mesh:

Year:  1988        PMID: 3403313     DOI: 10.1016/s0360-3016(98)90008-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  37 in total

1.  Efficacy of conventional radiotherapy for recurrent meningioma.

Authors:  M Kokubo; Y Shibamoto; J A Takahashi; K Sasai; N Oya; N Hashimoto; M Hiraoka
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Impaired survival and long-term neurological problems in benign meningioma.

Authors:  Hanna van Alkemade; Michelle de Leau; Edith M T Dieleman; Jan W P F Kardaun; Rob van Os; W Peter Vandertop; Wouter R van Furth; Lukas J A Stalpers
Journal:  Neuro Oncol       Date:  2012-03-09       Impact factor: 12.300

3.  Non-resectable slow-growing meningiomas treated by hydroxyurea.

Authors:  David Loven; Ruth Hardoff; Zvi Bar Sever; Adam P Steinmetz; Michael Gornish; Zvi H Rappaport; Eyal Fenig; Zvi Ram; Aaron Sulkes
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

Review 4.  Fractionated radiotherapy for intracranial meningiomas.

Authors:  Vinai Gondi; Wolfgang A Tome; Minesh P Mehta
Journal:  J Neurooncol       Date:  2010-09-01       Impact factor: 4.130

5.  Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma.

Authors:  A Gabriella Wernicke; Adam P Dicker; Michal Whiton; Jana Ivanidze; Terry Hyslop; Elizabeth H Hammond; Arie Perry; David W Andrews; Lawrence Kenyon
Journal:  Radiat Oncol       Date:  2010-05-30       Impact factor: 3.481

Review 6.  New prospects for management and treatment of inoperable and recurrent skull base meningiomas.

Authors:  Mahlon D Johnson; Burak Sade; Michael T Milano; Joung H Lee; Steven A Toms
Journal:  J Neurooncol       Date:  2007-07-12       Impact factor: 4.130

7.  Long-term outcome in meningiomas involving the major dural sinuses with combined therapy of subtotal resection and early postoperative gamma knife radiosurgery.

Authors:  Peng Lv; Jia-Jing Wang; Nan-Xiang Xiong; Xiao-Ming Liu; Dong-Xiao Yao; Xiao-Bing Jiang; Hong-Yang Zhao; Fang-Cheng Zhang; Peng Fu
Journal:  Acta Neurochir (Wien)       Date:  2021-02-20       Impact factor: 2.216

8.  Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Authors:  Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Andrew D Norden; Timothy F Cloughesy; Lauren E Abrey; Howard A Fine; Susan M Chang; H Ian Robins; Karen Fink; Lisa M Deangelis; Minesh Mehta; Emmanuelle Di Tomaso; Jan Drappatz; Santosh Kesari; Keith L Ligon; Ken Aldape; Rakesh K Jain; Charles D Stiles; Merrill J Egorin; Michael D Prados
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

9.  Stereotactic LINAC radiosurgery for the treatment of typical intracranial meningiomas. Efficacy and safety after a follow-up of over 12 years.

Authors:  Mustafa El-Khatib; Faycal El Majdoub; Stefan Hunsche; Mauritius Hoevels; Martin Kocher; Volker Sturm; Mohammad Maarouf
Journal:  Strahlenther Onkol       Date:  2015-08-08       Impact factor: 3.621

10.  [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning.

Authors:  Barbara Gehler; Frank Paulsen; Mehmet O Oksüz; Till-Karsten Hauser; Susanne M Eschmann; Roland Bares; Christina Pfannenberg; Michael Bamberg; Peter Bartenstein; Claus Belka; Ute Ganswindt
Journal:  Radiat Oncol       Date:  2009-11-18       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.